{"DataElement":{"publicId":"2646316","version":"1","preferredName":"Adjuvant Hormone Therapy Change Type","preferredDefinition":"the type of agent(s) switched or changed to produce therapeutic effects by means of change in hormone levels and given to augment or stimulate a primary therapy.","longName":"ADJ_HORMTX_CHG_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2009272","version":"3","preferredName":"Adjuvant Hormone Therapy Change","preferredDefinition":"related to the alteration or modification of the agents used to produce therapeutic effects by means of change in hormone levels which are given to augment or stimulate a primary therapy.","longName":"ADJ_HORMONTX_CHG","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206628","version":"1","preferredName":"Adjuvant Hormone Therapy","preferredDefinition":"Agents given to augment or stimulate a primary therapy or alleviate adverse effects caused by the primary therapy.(NCI):Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C2140:C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant","conceptCode":"C2140","definition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FD3D-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239855","version":"1","preferredName":"Change","preferredDefinition":"alteration or modification.","longName":"C25446","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Change","conceptCode":"C25446","definition":"The act of alteration or modification; changed or altered in form or character.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FA7953-81E7-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-24","modifiedBy":"ONEDATA","dateModified":"2005-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"22C9028F-C6C0-0B60-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"updated for ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2646315","version":"1","preferredName":"Hormone Therapy Change Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"HORMTX_CHG_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Aromatase Inhibitor","valueDescription":"Aromatase inhibitor","ValueMeaning":{"publicId":"2571015","version":"1","preferredName":"Aromatase inhibitor","longName":"2571015","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E274-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"ALAIS","dateModified":"2007-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31DAA0D2-F0DF-6CAC-E044-0003BA3F9857","beginDate":"2007-06-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-01","modifiedBy":"ALAIS","dateModified":"2007-06-01","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"TAMOXIFEN","ValueMeaning":{"publicId":"2561706","version":"1","preferredName":"TAMOXIFEN","longName":"2561706","preferredDefinition":"TAMOXIFEN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE17-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31DAA0D2-F0EB-6CAC-E044-0003BA3F9857","beginDate":"2007-06-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-01","modifiedBy":"ALAIS","dateModified":"2007-06-01","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31DAA0D2-F0F7-6CAC-E044-0003BA3F9857","beginDate":"2007-06-01","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-01","modifiedBy":"ALAIS","dateModified":"2007-06-01","deletedIndicator":"No"},{"value":"Gonadotropin Releasing Hormone plus Aromatase Inhibitor","valueDescription":"Gonadotropin Releasing Hormone plus Aromatase Inhibitor","ValueMeaning":{"publicId":"3857811","version":"1","preferredName":"Gonadotropin Releasing Hormone plus Aromatase Inhibitor","longName":"3857811","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04): A synthetic peptide that competes with the neurohormone GnRH for its receptor, thus decreasing or blocking GnRH action. As a result endogenous pituitary output of FSH and LH is shut down.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gonadotropin Releasing Hormone Antagonist","conceptCode":"C2092","definition":"Any agent that binds to the gonadotropin releasing hormone receptors and causes both the inhibition of gonadotropin releasing hormone activities and a decrease in the pituitary output of follicle stimulating hormone and luteinizing hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E450796F-6B90-0D63-E040-BB89AD433E01","latestVersionIndicator":"Yes","beginDate":"2013-08-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E450796F-6BA9-0D63-E040-BB89AD433E01","beginDate":"2013-08-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-19","modifiedBy":"ONEDATA","dateModified":"2013-08-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31DAA094-9BA4-6BED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-01","modifiedBy":"CAMPBELB","dateModified":"2013-08-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Specify new type of hormonal","type":"Preferred Question Text","description":"Specify new type of hormonal therapy given","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Specify new type of endocrine therapy given","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"31DB61AB-4744-53C6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-01","modifiedBy":"SHIDED","dateModified":"2010-10-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}